2023-509996-18-00已完成1 期
A Phase 1b, Open-Label, Dose-Escalation Trial of the Safety of and Antigen-Specific Immune Responses Elicited by VB.10 NEO in Combination With Atezolizumab in Subjects with Locally Advanced and Metastatic Tumors
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 7
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Mette Vinge
Scientific
Nykode Therapeutics ASA
研究点 (7)
Loading locations...
相似试验
招募中
1 期
A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin LymphomaClassical Hodgkin Lymphoma and Non-Hodgkin LymphomaJPRN-jRCT2031230576Seki Hidekuni12
进行中（未招募）
1 期
A first-in-human trial of safety and efficacy of GEN3017 in subjects with Hodgkin lymphoma or non-Hodgkin lymphomaHodgkin lymphoma or non-Hodgkin lymphomaMedDRA version: 20.0Level: HLGTClassification code: 10025322Term: Lymphomas non-Hodgkin's unspecified histology Class: 10029104MedDRA version: 20.0Level: HLGTClassification code: 10025319Term: Lymphomas Hodgkin's disease Class: 10029104CTIS2023-503348-15-00Genmab A/S240
进行中（未招募）
1 期
A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell LymphomaRelapsed, progressive and/or refractory mature B-cell lymphomaPatients with: - Diffuse large B-cell lymphoma – de novo or transformed - High-grade B-cell lymphoma - Primary mediastinal large B-cell lymphoma - Follicular lymphoma - Mantle cell lymphoma - Small lymphocytic lymphoma - Marginal zone lymphoma (nodal, extranodal or mucosaassociated)MedDRA version: 21.0Level: PTClassification code 10003903Term: B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-001748-36-FIGenmab A/S786
进行中（未招募）
1 期
A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell LymphomaCTIS2023-504802-12-00Genmab A/S682
进行中（未招募）
1 期
A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell LymphomaEUCTR2017-001748-36-SEGenmab A/S786